Repligen | RGEN - Cost Of Sales


Repligen reported $85.97M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Agilent USD 845M 7M Mar/2026
Align Technology USD 303.5M 60.47M Mar/2026
Bio Techne USD 103.13M 1.47M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Bruker USD 443.6M 84.4M Mar/2026
Charles River Laboratories USD 716.51M 5.76M Mar/2026
Danaher USD 2.36B 512M Mar/2026
Dentsply International USD 453M 65M Mar/2026
General Electric Aerospace USD 8.15B 764M Mar/2026
Henry Schein USD 2.3B 145M Mar/2026
Illumina USD 370M 30M Mar/2026
IQVIA Holdings USD 3.08B 161M Mar/2026
Mettler Toledo International USD 410.92M 63.05M Mar/2026
Myriad Genetics USD 63M 1.1M Dec/2025
OraSure Technologies USD 15.43M 113K Dec/2025
Pacific Biosciences Of California USD 28.9M 10M Dec/2025
Pfizer USD 4.59B 1.7B Mar/2026
Repligen USD 85.97M 8.11M Mar/2026
Revvity USD 323.46M 26.93M Mar/2026
Standard Biotools USD 12.41M 2.34M Dec/2025
Thermo Fisher Scientific USD 6.96B 620M Mar/2026
Waters USD 725M 350.06M Mar/2026
West Pharmaceutical Services USD 548.5M 47.4M Mar/2026